UnitedHealth Group (NYSE: UNH) recently crashed after the U.S. Department of Justice might start a criminal investigation into the company. While this is a risk for investors, it is also an opportunity due to the cheap valuation and insider buying.
Overall, UNH is a solid company. While it has only small gross profit margins of 21.99%, its EBITDA margin of 8.16% and strong ROE of 24.33% are far above the industry average.
Furthermore, the company has a slightly above average current revenue growth of 8.06% and forward revenue growth of 9.04%, while ROE is growing by over 30%.
In terms of valuation, the company is currently very cheap due to all the bad news that is currently circulating. The EV/EBITDA ratio of 9.72 almost shows a 30% discount to the industry’s median value. Furthermore, the P/S ratio of 0.72 is extremely low, considering that the industry average is at 3.34. While the P/B ratio is high at 3.08, the company also has a low P/E ratio of 13.5, a 50% discount to the industry median. This is especially low when compared to the P/E ratio over time, displayed in Figure 1. As can be seen, the ratio has not once been under 20 (at the end of the year) since 2018. Considering that the average P/E ratio, shown in Figure 1, has been 24.33, we are currently trading at a 45% discount to historical valuation.
The $5M Insider Vote of Confidence in United Health
When looking at the profitability of some of UNH’s peers, the company is one of the more profitable ones. Out of a peer group of 5 other companies, only Elevance Health (NYSE: ELV) has a higher gross profit margin at 27.74%. At the same time, no other company has a higher EBITDA margin and ROE than UNH, with ELV again being second but far away from UNH at values of 5.37% and 14.24%, respectively. An additional strength of UNH is the company’s strong 10-year CAGR of 12.4% vs the sector average of 8.9%, again suggesting that the company is one of the highest quality ones in its field. While free cash flow yield is not as strong as other valuation metrics, it is still solid at 5.1%, compared to 4.3% for Elevance and 6% for Cigna.
When looking at growth, UNH is still strong compared to the peer group, but Cigna Group (NYSE: CI) and Humana (NYSE: HUM) both have higher revenue growth. Nevertheless, when looking at diluted EPS and ROE growth, only CI has higher numbers than UNH at 46.1% and 47.25%, respectively. In total, this shows that UNH is one of the fundamentally strongest companies in its peer group.
Story Continues